Catálogos >
Randox Laboratories >
MRSA/SA – Emerging Therapeutic & Screening Approaches

MRSA/SA – Emerging Therapeutic & Screening Approaches
1 / 8Páginas

Excertos do catálogo

MRSA/SA – Emerging Therapeutic & Screening Approaches - 1

EDUCATIONAL GUIDE MRSA/SA – Emerging Therapeutic & Screening Approaches

MRSA/SA – Emerging Therapeutic & Screening Approaches - 2

Introduction Staphylococcus aureus is a gram positive, commensal bacteria found in normal human flora on the skin and mucous membranes. The commensal nature of this organism results in colonisation of around half of the general population, rising to around 80% in populations of healthcare workers, hospitalised patients and the immunocompromised1. However, given the opportunity to colonise internal tissues or the bloodstream, S. aureus infection can cause serious disease. Skin conditions caused by S. aureus include impetigo, scalded skin syndrome, boils, and abscesses. Examples of more...

Abrir o catálogo na página 2

MRSA/SA – Emerging Therapeutic & Screening Approaches - 3

Identification of drug-resistant strains of bacteria is crucial to allow for characterisation of the pathogen and correct treatment of the infection. Classical evaluation consists of a routine culture to verify a diagnosis based on presenting symptoms. However, this can be a time consuming and laborious process which may delay diagnosis and treatment of a potentially fatal infection1. Methicillin-Resistant Staphylococcus aureus Methicillin is of a class of antibiotics known as β-lactams which bind to the penicillin binding protein (PBP) of the bacteria. PBP is responsible for crosslinking...

Abrir o catálogo na página 3

MRSA/SA – Emerging Therapeutic & Screening Approaches - 4

The first mechanism of resistance is the expression of β-lactamase which functions to degrade β-lactams, ultimately resulting in loss of function of the antibiotic. This enzyme hydrolyses β-lactam ions in the periplasmic space, denaturing the antibiotic before it can interact with bacteria3. The mecA gene encodes the protein penicillin-binding protein 2a (PBP-2a), a type of PBP which has lower affinity for β-lactams, as well as other penicillin-like antibiotics, due its conformation, meaning that the presence of these antimicrobial agents does not confer a loss of structure in the bacterial...

Abrir o catálogo na página 4

MRSA/SA – Emerging Therapeutic & Screening Approaches - 5

Non-membrane disruptive AMPs require much more investigation; however, it is accepted that these AMPs enter the cell, reacting with important intracellular components inhibiting protein and nucleic acid synthesis, cell division and protease activity3. Silver nanoparticles (AgNPs) exhibit broad spectrum antimicrobial properties through various mechanisms of action. These nanosized particles boast increased antimicrobial properties due to an increased surface area per volume ratio. The first mechanism of action to note is AgNPs direct adhesion to the bacterial membrane, which alters the...

Abrir o catálogo na página 5

MRSA/SA – Emerging Therapeutic & Screening Approaches - 6

Vivalytic MRSA/SA Bosch Vivalytic MRSA/SA is an automated, qualitative, in vitro diagnostic test based on real-time PCR for the detection and differentiation of Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA) DNA from human nasal- or oropharyngeal swabs to aid in the diagnosis of MRSA infection of symptomatic or asymptomatic individuals, providing results in less than 1 hour. Rapid PCR MRSA/SA Screening - Bacterial Differentiation to Promote Targeted Therapy Patient presents with symptoms Specimen collected and sent for testing 4 -...

Abrir o catálogo na página 6

MRSA/SA – Emerging Therapeutic & Screening Approaches - 7

Murray CJ, Ikuta KS, Sharara F, et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. The Lancet. 2022;399(10325):629-655. doi:https://doi.org/10.1016/S0140-6736(21)02724-0 2. Nandhini P, Kumar P, Mickymaray S, Alothaim AS, Somasundaram J, Rajan M. Recent Developments in Methicillin-Resistant Staphylococcus aureus (MRSA) Treatment: A Review. Antibiotics. 2022;11(5):606. doi:https://doi.org/10.3390/antibiotics11050606 3. Masimen MAA, Harun NA, Maulidiani M, Ismail WIW. Overcoming Methicillin-Resistance Staphylococcus aureus (MRSA) Using Antimicrobial...

Abrir o catálogo na página 7

MRSA/SA – Emerging Therapeutic & Screening Approaches - 8

Copyright © 2023 Randox Laboratories Ltd. All rights Reserved. VAT number: GB 151682708. Product availability may vary from country to country. Some products may be for Research Use Only. For more information on product application and availability, please contact your local Randox Representative.

Abrir o catálogo na página 8